Can Targeted Therapy Revolutionize MIBC Treatment?
Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.
The phase 2 SunRISe-4 study (NCT04919512) evaluated the efficacy and safety of neoadjuvant TAR-200 and cetrelimab, an anti–PD-1 agent, in patients with muscle-invasive bladder cancer (MIBC). The study found that patients receiving TAR-200 and cetrelimab had significantly higher rates of pathologic complete response (pCR) compared to those receiving cetrelimab alone. Additionally, the safety profile of TAR-200 and cetrelimab was manageable. These results suggest that TAR-200 may be a promising treatment option for patients with MIBC, particularly those with early-stage disease.
Here, Andrea Necchi, MD, associate professor of oncology at Vita-Salute San Rafaelle University and director of genitourinary oncology at San Raffaele Hospital in Milan, Italy, discusses how these findings build upon others from the SunRISe series of clinical trials.
Transcription:
0:05 | The SunRISe platform is testing TAR-200 in different disease settings, non–muscle-invasive disease, and we have already pretty well positioned in getting a potential new therapeutic option there for [Bacillus Calmette-Guerin (BCG)]-uresponsive tumors in patient with muscle-invasive disease. The point here is how to best manage the future patients with regards to the potential of curing patients and avoiding the radical surgery, cystectomy. It is quite highly impactful for that, for the patients, and quite impactful for the healthcare system, for the cost and the management of the patients in general.
0:45 | So the possibility of getting a cure, achieving a cure for the patient side with the combination, with a newer combination, and potentially also avoiding radical cystectomy that is also affecting the quality of life of the patients is is a major step, is a potential major step for further research in these patients.
